{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-224065","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2026-05-14T20:15:18+00:00","discovered_at":"2026-05-14T20:17:10.145877+00:00","generated_at":"2026-05-14T20:52:59.263924+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sutro Q1 cash $202.6M; revenue $14.5M; luvelta closed; STRO-004 data mid-2026","bullets":["Cash $202.6M as of Mar 31, 2026 (vs $141.4M Dec 2025); $110M stock offering extends runway into Q2 2028.","Q1 revenue $14.5M (down from $17.4M YoY); total R&D+G&A $44.1M (down from $64.9M YoY).","STRO-004 Phase 1 dose-escalation ongoing; initial safety, PK, activity data expected mid-2026.","Astellas collaboration: first TROP2 dual-payload iADC in clinic; $10M milestone received April 2026.","Luvelta program closed; no further investment or business development efforts."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-224065","json":"https://secwatch.observer/filing/0001193125-26-224065.json","markdown":"https://secwatch.observer/filing/0001193125-26-224065.md","text":"https://secwatch.observer/filing/0001193125-26-224065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000119312526224065/0001193125-26-224065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000119312526224065/stro-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:52:59.263924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64eecd96dc939fbfa89200331054d221c59f4ba5","claim":"SUTRO BIOPHARMA, INC. reported financial results for the first quarter of 2026.","evidence_excerpt":"Sutro Biopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1382101/000119312526224065/0001193125-26-224065-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}